Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS

Infezioni in Medicina

Volumn 12, Issue 3, 2004, Pages 197-204

  Mastroianni, Antonio ^a  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

HIV; RHuGM CSF; Visceral leishmaniosis

Indexed keywords

ABACAVIR; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CLINDAMYCIN; DIDANOSINE; LAMIVUDINE; NELFINAVIR; PYRIMETHAMINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEISHMANIA; LEISHMANIASIS; LEUKOCYTE COUNT; MALE; NEUTROPENIA; SIDE EFFECT; VIRUS LOAD; VISCERAL LEISHMANIASIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; DRUG THERAPY, COMBINATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HOST-PARASITE INTERACTIONS; HOST-PARASITE RELATIONS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOSOMES; MACROPHAGES; MALE; RECOMBINANT PROTEINS;

EID: 7044271115     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. World Health Organization. Division of Control of Tropical Diseases. Leishmaniasis control home page. www.who.int/health-topics/leishmaniasis.htm (updated 2000).
2. World Health Organization (WHO). Leishmania/HIV co-infection: south-western Europe 1990-1998 (WHO/LEISH/2000.42). Geneva: WHO, 2000.
3. Moreno J., Cañavate C., Chamizo C., Laguna F., Alvar J. HIV-leishmania infantum co-infection: humoral and cellular immune responses to the parasites. Trans. R. Soc. Trop. Med. Hyg. 94, 328-332, 2000.
4. Hamour A.A., Skelly R., Jowitt S.N., et al. Visceral leishmaniasis (Kala-azar) in two patients with HIV-1 infection: atypical features and response to therapy. J. Infect. Dis. 36, 217-220, 1998.
5. Condon M.J., Cloet B., Sirera G., et al. Asymptomatic leishmaniasis in the acquired immunodeficiency syndrome (AIDS) [letter]. Ann. Int. Med. 111, 767, 1989.
6. Mofredi A., Guerin J.M., Leibinger F., Masoudi R. Visceral leishmaniasis with pericarditis in an HIV-infected patient. Scand. J. Infect. Dis. 34, 151-153, 2001.
7. Angarano G., Maggi P., Rollo M.A., et al. Diffuse necrotic hepatic lesions due to visceral leishmaniasis in AIDS. J. Infect. Dis. 36, 167-169, 1998.
8. Rosenthal E., Marty P., del Giudice P., Pradier C., et al. HIV and Leishmania co-infection: a review of 91 cases with focus on atypical locations of Leishmania. Clin. Infect. Dis. 31, 1093-1095, 2001.
9. Caballero-Granado F.J., Lopez-Cortes L.F., Borderas F., Regordon C. Digital necrosis due to leishmania species infection in a patient with AIDS. Clin. Infect. Dis. 26, 198-199, 1998.
10. Desjeux P., Piot B., O'Neill K., Meert J.P. Co-infections of leishmania/HIV in south Europe. Med. Trop. 61, 187-193, 2001.
11. Lopez-Velez R., Perez-Molina J.A., Guerrero A., et al. Clinical-epidemiologic characteristics, prognostic factors, and survival analysis of patients co-infected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am. J. Trop. Med. Hyg. 58, 436-443, 1998.
12. Alvar J., Canavate C., Gutierrez-Solar B., et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10, 298-319, 1997.
13. Preiser W., Cacopardo B., Nigro L., et al. Immunological findings in HIV-Leishmania coinfection. Intervirology 39 (4), 285-288, 1996.
14. Wolday D, Akuffo H., Fesshaye G., et al. Live and killed human immunodeficiency virus type-1 increase the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand. J. Infect. Dis. 30, 29-34, 1998.
15. Dasgupta B., Roychoudhury K., Gonguly S., et al. Infection of human mononuclear phagocytes and macrophages-like THP1 cells with Leishmania donovani results in modulation of expression of a subset of chemokines and a chemokine receptor. Scand. J. Immunol. 57, 366-374, 2003.
16. Verthelyi D., Gursel M., Kenney R.T., et al. CpG godeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol. 170, 4717-4723, 2003.
17. Peters B.S., Fish D., Golden R., Evans D.A., Bryceson A.D.M., Pinching A.J. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q. J. Med. 77, 1101-1111, 1990.
18. Morales M.A., Cruz I., Rubio J.M., et al. Relapses versus re-infection in patients co-infected with Leishmanía infantum mania infantum and human immunodeficiency virus type 1. Clin. Infect. Dis. 185, 1533-1537, 2002.
19. Sundar S., Sahu M., Gupta A., et al. Non-invasive management of Indian visceral leishmaniasis. Clinical application of diagnosis by K39 antigen testing at a Kala-azar referral unit. Clin. Infect. Dis. 35, 581-586, 2002.
20. Sundar S., More D.K., Singh M.K., et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the indian epidemic. Clin. Infect. Dis. 31, 1104-1107, 2000.
21. Osman O.F., Oskam L., Zijlstra E.E., El-Hassan A.M., El-Naeim D.A., Kager P.A. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment. Trans. R. Soc. Trop. Med. Hyg. 92, 397-400, 1998.
22. Osman OF, Kager PA, Oskam L. Leishmaniasis in the Sudan: a literature review with emphasis on clinical aspects. Trop. Med. Intern. Health 5, 553-562, 2000.
23. Cascio A, Gradoni L, Scarlata F, et al. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy. Am. J. Trop. Med. Hyg. 57, 75-78, 1997.
24. Sundar S., Rai M. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15, 593-598, 2002.
25. Sundar S., Rosenkaimer F., Lesser M.L., et al. Immunotherapy for a systemic intracellular infection: accelerated response using interferon-γ in visceral leishmaniasis. J. Infect. Dis. 171, 992-996, 1995.
26. Thakur C.P., Sinha P.K., Singh R.K., Hassan S.M., Narain S. Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in India. Trans. R. Soc. Trop. Med. Hyg. 94, 696-697, 2000.
27. de la Rosa R., Pineda J.A., Delgado J., et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 32, 633-635, 2001.
28. Del Giudice P., Mary-Krause M., Pradier C., et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J. Infect. Dis. 186, 1366-1370, 2002.
29. Mastroianni C.M., d'Ettore G., Forcina G., et al. Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: report of two cases. J. Infect. 40, 1, 94-96, 2000.
30. Jones T.C. The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease. Med. Oncol. 13, 141-147, 1996.
31. Weiser W.Y., van Niel A., Clark S.C., David J.R., Remold H.G. Recombinant human granulocyte-macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages. J. Exp. Med. 166, 1436-1446, 1987.
32. Ho J.L., Reed S.G., Wick E.A., Giordano M. Granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factors activate intramacrophage killing of Leishmania amazonensis. J. Infect. Dis. 162, 224-330, 1990.
33. Hatzigeorgiou D.E., He S., Sobel J., et al. IL-6 down-modulates the cytokine-enhanced antileishmania activity in human macrophages. J. Immunol. 151, 3682-3692, 1993.
34. Murray H.W., Cervia J.S., Hariprashad J., et al. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J. Clin. Invest. 95, 1183-1192, 1995.
35. Al-Zanel F., Al-Shammary F.J., El-Shewemi S., Soliman R. Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte macrophage colony stimulating factor. Zentralbl Bakteriol. 285, 92-105, 1996.
36. Badaro R., Nascimento C., Carvalho J.S., et al. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis. 170, 413-418, 1994.